GlassScriptPhysician profile
Andre M Kallab
NPI 1669475760
$19,666.85
in general payments reported to CMS, 2019-2025
65 companies · $7,023 in 2025
The $7,023 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,693 · 2020: $1,697 · 2021: $2,409 · 2022: $2,306 · 2023: $2,003 · 2024: $2,537 · 2025: $7,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,069 · Consulting Fee: $3,268 · Long Term Medical Supply Or Device Loan: $997 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,068.60 |
| Consulting Fee | $3,268.00 |
| Long Term Medical Supply Or Device Loan | $997.00 |
| Education | $228.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $3,406.33 | 2024-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $1,407.25 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,405.15 | 2019-2025 | Tagrisso, Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $1,192.96 | 2019-2025 | Opdivo, Opdualag |
| Celgene Corporation | $1,110.19 | 2020-2025 | Reblozyl, Opdualag |
| Seagen INC. | $928.65 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Abbvie INC. | $634.08 | 2022-2025 | |
| Janssen Biotech, INC. | $632.76 | 2019-2025 | Talvey, Darzalex, Erleada |
| Incyte Corporation | $619.23 | 2020-2025 | Jakafi, Monjuvi, Zynyz |
| Exelixis INC. | $549.71 | 2020-2025 | Cabometyx |
| Pfizer INC. | $517.24 | 2020-2025 | |
| Genzyme Corporation | $516.31 | 2019-2025 | |
| Eisai INC. | $462.33 | 2020-2025 | |
| Amgen INC. | $458.70 | 2019-2023 | Lumakras, Vectibix, Xgeva |
| Glaxosmithkline, LLC. | $432.76 | 2020-2025 | Ojjaara, Jemperli, Blenrep |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $429.32 | 2019-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $407.86 | 2019-2025 | Keytruda, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $392.79 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $331.17 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $328.96 | 2019-2021 | |
| Daiichi Sankyo INC. | $318.22 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Genentech USA, INC. | $266.15 | 2019-2025 | Venclexta, Polivy |
| Takeda Pharmaceuticals U.S.A., INC. | $219.66 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Beigene USA, INC. | $191.98 | 2021-2025 | Brukinsa |
| Astellas Pharma US INC | $168.51 | 2019-2025 | Padcev |
| Gilead Sciences, INC. | $158.07 | 2021-2025 | Trodelvy |
| Verastem, INC. | $125.00 | 2019 | |
| Epizyme, INC. | $120.10 | 2021-2023 | Tazverik |
| Array Biopharma INC | $110.16 | 2020-2025 | Braftovi, Mektovi, Tukysa |
| Tempus Ai, INC | $109.63 | 2024-2025 | Xt Cdx |
| Caris Mpi, INC. | $97.95 | 2025 | Mi Cancer Seek |
| Blueprint Medicines Corporation | $92.79 | 2020-2022 | |
| Adaptive Biotechnologies Corporation | $89.18 | 2024-2025 | Clonoseq |
| Lilly USA, LLC | $87.86 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Tersera Therapeutics LLC | $82.25 | 2021-2025 | Zoladex |
| Kite Pharma, INC. | $79.43 | 2020-2025 | Yescarta |
| Karyopharm Therapeutics INC. | $77.99 | 2021-2025 | Xpovio |
| Deciphera Pharmaceuticals INC. | $77.77 | 2021-2025 | Qinlock, Tgct, Romvimza |
| Adc Therapeutics America, INC. | $77.05 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $75.43 | 2019-2023 | Tavalisse, Rezlidhia |
| Heron Therapeutics, INC. | $66.39 | 2019-2020 | |
| Beone Medicines USA, INC. | $61.45 | 2025 | Brukinsa |
| Morphosys, US INC. | $59.68 | 2021-2023 | Monjuvi |
| G1 Therapeutics, INC. | $59.03 | 2023 | Cosela |
| Coherus Oncology, INC. | $57.18 | 2020-2021 | |
| Sobi, INC | $55.18 | 2024-2025 | |
| Puma Biotechnology, INC. | $54.41 | 2022-2024 | |
| Agios Pharmaceuticals, INC. | $47.48 | 2022-2024 | Pyrukynd |
| Taiho Oncology, INC. | $46.90 | 2019-2021 | |
| Pharmaessentia USA Corporation | $44.16 | 2025 | Besremi |
| Mirati Therapeutics, INC. | $40.73 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $33.85 | 2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $33.34 | 2023 | Libtayo |
| Emd Serono, INC. | $31.87 | 2021-2022 | |
| Dova Pharmaceuticals | $23.70 | 2020 | |
| Sumitomo Pharma America, INC. | $22.10 | 2023 | Orgovyx |
| Tolmar Pharmaceuticals, INC. | $20.32 | 2020 | |
| Cti Biopharma Corp. | $20.03 | 2023 | Vonjo |
| Legend Biotech USA INC. | $19.82 | 2025 | Carvykti |
| Corcept Therapeutics | $18.51 | 2025 | Korlym |
| Progenics Pharmaceuticals, INC. | $18.01 | 2025 | |
| Aveo Pharmaceuticals, INC. | $17.30 | 2022 | |
| Fortovia Therapeutics, INC. | $13.36 | 2019 | |
| Clovis Oncology, INC. | $13.12 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Kallab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.